Kofler T, Kurmann R, Lehnick D, et al. - Colchicine (anti‐inflammatory drug) use in coronary artery disease (CAD) patients resulted in decreased risk of myocardial infarction and stroke but was associated with a higher rate of gastrointestinal upset with no impact on all‐cause mortality.

• A pivotal role of inflammation in CAD has been reported.

• This systematic review and meta‐analysis involved 13 randomized trials (n=13,125).

• Included studies compared colchicine with placebo/standard therapy in CAD patients.

• These studies were obtained from MEDLINE, EMBASE, Cochrane CENTRAL and conference abstracts.

• Trial sequential analyses showed that only sufficient evidence exists for a myocardial infarction risk reduction with colchicine.